Kodiak Sciences (KOD) announced that it has commenced an underwritten public offering of 6M of shares of its common stock. J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank are acting as joint book-running managers for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences’ Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic Adjustments
- Kodiak Sciences price target raised to $26 from $24 at H.C. Wainwright
- Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy Rating
- Kodiak Sciences Faces Financial Challenges Amid R&D Focus
- Kodiak Sciences reports Q3 EPS ($1.16), consensus ($1.04)